155 related articles for article (PubMed ID: 2408269)
1. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.
Liebman HA; Limentani SA; Furie BC; Furie B
Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3879-83. PubMed ID: 2408269
[TBL] [Abstract][Full Text] [Related]
2. Immunoaffinity purification of protein C by using conformation-specific monoclonal antibodies to protein C-calcium ion complex.
Nakamura S; Sakata Y
Biochim Biophys Acta; 1987 Aug; 925(2):85-93. PubMed ID: 3620498
[TBL] [Abstract][Full Text] [Related]
3. Separation of human plasma factor IX from HTLV-I or HIV by immunoaffinity chromatography using conformation-specific antibodies.
Limentani SA; Furie BC; Poiesz BJ; Montagna R; Wells K; Furie B
Blood; 1987 Nov; 70(5):1312-5. PubMed ID: 2822170
[TBL] [Abstract][Full Text] [Related]
4. Rapid purification of factor IX, factor X and prothrombin by immunoaffinity and ion exchange chromatography.
Ahmad SS; Rawala-Sheikh R; Thompson AR; Walsh PN
Thromb Res; 1989 Jul; 55(1):121-33. PubMed ID: 2781515
[TBL] [Abstract][Full Text] [Related]
5. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody.
Goodall AH; Kemble G; O'Brien DP; Rawlings E; Rotblat F; Russell GC; Janossy G; Tuddenham EG
Blood; 1982 Mar; 59(3):664-70. PubMed ID: 7059674
[TBL] [Abstract][Full Text] [Related]
6. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
Ware J; Diuguid DL; Liebman HA; Rabiet MJ; Kasper CK; Furie BC; Furie B; Stafford DW
J Biol Chem; 1989 Jul; 264(19):11401-6. PubMed ID: 2738071
[TBL] [Abstract][Full Text] [Related]
7. Rabbit polyclonal antibodies against the calcium-dependent conformation of factor IX and their application in solid phase immunoradiometric assays.
Poort SR; van der Linden IK; Krommenhoek-van Es C; Briët E; Bertina RM
Thromb Haemost; 1986 Feb; 55(1):122-8. PubMed ID: 3704999
[TBL] [Abstract][Full Text] [Related]
8. Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells.
Kaufman RJ; Wasley LC; Furie BC; Furie B; Shoemaker CB
J Biol Chem; 1986 Jul; 261(21):9622-8. PubMed ID: 3733688
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CNBr, FMP and hydrazide resins for immunoaffinity purification of factor IX.
Highsmith F; Regan T; Clark D; Drohan W; Tharakan J
Biotechniques; 1992 Mar; 12(3):418-23. PubMed ID: 1571154
[TBL] [Abstract][Full Text] [Related]
10. Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion.
Bray GL; Thompson AR
J Clin Invest; 1986 Apr; 77(4):1194-200. PubMed ID: 3514676
[TBL] [Abstract][Full Text] [Related]
11. Immunopurification of human coagulation factor IX using monoclonal antibodies.
Bessos H; Prowse CV
Thromb Haemost; 1986 Aug; 56(1):86-9. PubMed ID: 3775693
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies to factor IX: characterization and use in immunoassays for factor IX.
Smith KJ; Ono K
Thromb Res; 1984 Jan; 33(2):211-24. PubMed ID: 6422579
[TBL] [Abstract][Full Text] [Related]
13. Development of an immunoaffinity process for factor IX purification.
Tharakan J; Strickland D; Burgess W; Drohan WN; Clark DB
Vox Sang; 1990; 58(1):21-9. PubMed ID: 2316207
[TBL] [Abstract][Full Text] [Related]
14. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
Burnouf T; Michalski C; Goudemand M; Huart JJ
Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
[TBL] [Abstract][Full Text] [Related]
15. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa.
Liebman HA; Furie BC; Furie B
J Biol Chem; 1987 Jun; 262(16):7605-12. PubMed ID: 3108254
[TBL] [Abstract][Full Text] [Related]
16. Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
Suehiro K; Miyata T; Takeya H; Takamatsu J; Saito H; Murakawa M; Okamura T; Niho Y; Iwanaga S
Thromb Res; 1990 Nov; 60(4):311-20. PubMed ID: 2087690
[TBL] [Abstract][Full Text] [Related]
17. Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography.
Feldman PA; Bradbury PI; Williams JD; Sims GE; McPhee JW; Pinnell MA; Harris L; Crombie GI; Evans DR
Blood Coagul Fibrinolysis; 1994 Dec; 5(6):939-48. PubMed ID: 7893930
[TBL] [Abstract][Full Text] [Related]
18. The abnormal factor IX of hemophilia B+ variants.
Bertina RM; Veltkamp JJ
Thromb Haemost; 1978 Oct; 40(2):335-49. PubMed ID: 734633
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
Yoshioka A; Ohkubo Y; Nishimura T; Tanaka I; Fukui H; Ogata K; Kamiya T; Takahashi H
Thromb Res; 1986 Jun; 42(5):595-604. PubMed ID: 3487139
[TBL] [Abstract][Full Text] [Related]
20. Structural transitions in bovine factor X associated with metal binding and zymogen activation. Studies using conformation-specific antibodies.
Keyt B; Furie BC; Furie B
J Biol Chem; 1982 Aug; 257(15):8687-95. PubMed ID: 6178736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
